On September 25, the California Attorney General Rob Bonta announced a settlement with a biotech company, Biora Therapeutics, Inc. (Biora). The settlement addressed misleading claims the company made about the cost of its genetic testing services. As mandated by the settlement agreement, Biora is now obligated to waive all outstanding debts for their California customers. In addition, the company must pay $200,000 in penalties. This settlement underscores the state’s commitment to holding corporations accountable for honest marketing practices, especially in the expanding field of genetic testing services.
According to JD Supra, the precise details of the alleged deceptive practices were not disclosed. However, it is clear that the company’s representations of its product and pricing stirred enough concern for the Attorney General’s office to intervene. Given the increased consumer interest in genetic testing and the complex nature of health care pricing, misleading promotions can have significant impacts on consumers.
This settlement serves as a crucial reminder for all corporations, particularly those operating in the sectors of biotechnology and healthcare. The legal community will be watching developments like these very closely to assess the ongoing regulatory landscape for genetic testing services. As we all navigate the ever-evolving niches of science and technology, companies must remain rigorously attentive to their compliance obligations under marketing and consumer protection laws.